NEW YORK, Dec. 5, 2017 /PRNewswire/ -- WeissLaw LLP is
investigating possible breaches of fiduciary duty and other
violations of law by the Board of Directors of Aetna Inc. ("AET" or
the "Company") (NYSE: AET) in connection with the proposed
acquisition of the Company by CVS Health Corporation ("CVS") (NYSE:
CVS). Under the terms of the agreement, the Company's
shareholders will receive $145 in
cash and 0.8378 of a share of CVS for each AET share they hold,
representing consideration of $203.80, based on CVS's December 5 trading price of $70.19.
WeissLaw is investigating whether AET's Board acted to maximize
shareholder value prior to entering into the agreement.
Notably, at least one analyst set a target price of $214.00, nearly $10
more than the per-share consideration. Additionally, the
Company announced strong earnings in the third quarter of 2017,
reporting quarterly adjusted earnings of $2.45 per share, representing annual growth of
approximately 18% when compared to the same period of the previous
year.
Finally, CVS anticipates that this transaction will create a
leading healthcare platform with highly diversified, strong and
stable cash flows. The deal is also expected to generate
substantial synergies, with the potential synergies of $750 million in the second full
year.
Given these facts, WeissLaw is investigating whether AET's Board
acted in the best interests of AET's public shareholders to
maximize shareholder value prior to entering into the
agreement. If you own AET shares and would like more
information about your rights or our investigation, or if you have
information to share with us, please contact Joshua Rubin by telephone at
(888) 593-4771 or by email at
stockinfo@weisslawllp.com.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com or visit our website,
http://www.weisslawllp.com/aetna-inc/
View original
content:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-the-acquisition-of-aetna-inc-300567185.html
SOURCE WeissLaw LLP